Neumora Therapeutics is trading at $0.44, down 6.04%, as of 10:32 a.m. EST on October 21, 2026; no fresh company-specific announcement explaining the decline was found.
- Supplied price context shows a sharp premarket gain reversing during regular trading; live volume was not provided.
- Recent reporting discussed navacaprant trial disappointments, but that prior news does not establish the reason for this session’s move.
- XBI is up 2.10%, opposite Neumora’s move, so biotech-sector strength is not a clear explanation.